Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3).

MLA

Papp, K. A., et al. “Ixekizumab Treatment for Psoriasis: Integrated Efficacy Analysis of Three Double‐blinded, Controlled Studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3).” British Journal of Dermatology, vol. 178, no. 3, Mar. 2018, pp. 674–81. EBSCOhost, https://doi.org/10.1111/bjd.16050.

APA

Papp, K. A., Leonardi, C. L., Blauvelt, A., Reich, K., Korman, N. J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G. S., Erickson, J., Zhang, L., Mallbris, L., & Griffiths, C. E. M. (2018). Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3). British Journal of Dermatology, 178(3), 674–681. https://doi.org/10.1111/bjd.16050

Chicago

Papp, K. A., C. L. Leonardi, A. Blauvelt, K. Reich, N. J. Korman, M. Ohtsuki, C. Paul, et al. 2018. “Ixekizumab Treatment for Psoriasis: Integrated Efficacy Analysis of Three Double‐blinded, Controlled Studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3).” British Journal of Dermatology 178 (3): 674–81. doi:10.1111/bjd.16050.